Zhejiang Ausun Pharmaceutical Co., Ltd.
603229.SS
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.8B
Close$
$-0.70
108.6% downside
Current Fair Value
108.6% downsideOvervalued by 108.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.80 Billion |
|---|---|
| Enterprise Value | $6.27 Billion |
| Dividend Yield | $0.06 (0.78%) |
| Earnings per Share | $0.16 |
| Beta | -0.18 |
| Outstanding Shares | 825,095,945 |
Return
| Return on Equity | 3.39% |
|---|---|
| Return on Assets | 2.63% |
| Return on Invested Capital | 2.15% |
Valuation & Multiples
| P/E Ratio | 81.17 |
|---|---|
| PEG | -150.93 |
| Price to Sales | - |
| Price to Book Ratio | 4.1 |
| Enterprise Value to Revenue | 8.05 |
| Enterprise Value to EBIT | 117.54 |
| Enterprise Value to Net Income | 77 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.2 |
Revenue Sources
No data
Insider Trades
Next Earnings Call
Expected Date
October 31, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$140.02 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Zhejiang Ausun Pharmaceutical Co., Ltd.
1,328 employees
CEO: Zhiguo Zheng Established in 2010 and headquartered in Linhai, China, Zhejiang Ausun Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of unique active pharmaceutical ingredients (APIs) and various intermediate co...